In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding. They advocate for shortening the time period between registration of antiretroviral drugs and first pregnancy data becoming available.Recently, the FDA and EMA issued warnings on the use of dolutegravir and darunavir/cobicistat for treatment of pregnant women living with HIV. It took 3 to 5 years to identify the risks associated with the use of these antiretroviral drugs, during which time pregnant women were exposed to these drugs in clinical care, outside of controlled clinical trial settings. Across all antiretroviral drugs, the interval between registration of new drugs and first data on pharmacokinetics and safety in pregnancy becoming available is around 6 years.
Importance of prospective studies in pregnant and breastfeeding women living with HIV.
Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D.
Angela Colbers, Stein Schalkwijk and David Burger are members of theme Infectious diseases and global health.
Related news items
The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger2 November 2021
On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.read more
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.read more
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV17 March 2020
In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.read more
Pharmacy receives prestigious European prize for research in Africa27 September 2018
On 17 September, David Burger, professor of clinical pharmacy, together with colleagues from the United Kingdom, Uganda and Zimbabwe, received the "Outstanding Research Team" award from the European - Developing Countries Clinical Trial Partnership (EDCTP).read more